Perindopril erbumine 8mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Perindopril erbumine

Available from:

Accord-UK Ltd

ATC code:

C09AA04

INN (International Name):

Perindopril erbumine

Dosage:

8mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 02050501; GTIN: 5060149312964

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PERINDOPRIL 2 MG TABLETS
PERINDOPRIL 4 MG TABLETS
PERINDOPRIL 8 MG TABLETS
Perindopril tert-butylamine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor,pharmacist or
nurse.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their
signs of illness are the same as yours
.

If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
.
WHAT IS IN THIS LEAFLET:
1. What Perindopril Tablets are and what they are used for
2. What you need to know before you take Perindopril Tablets
3. How to take Perindopril Tablets
4. Possible side effects
5. How to store Perindopril Tablets
6. Contents of the pack and other information
1. WHAT PERINDOPRIL TABLETS ARE AND WHAT THEY ARE USED FOR
Perindopril belongs to a group of medicines called ACE inhibitors.
These work by widening
the blood vessels. This makes it easier for your heart to pump blood
through the body.
Perindopril Tablets are used to:

treat high blood pressure (hypertension).

treat heart failure (a condition where the heart is unable to pump
enough blood to meet
the body’s needs).

reduce the risk of cardiac events, such as heart attack, in patients
with stable coronary
artery disease (a condition where the blood supply to the heart is
reduced or blocked) and
who have already had a heart attack and/or an operation to improve the
blood supply to
the heart by widening the vessels that supply it.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PERINDOPRIL TABLETS
DO NOT TAKE PERINDOPRIL TABLETS

if you are allergic (hypersensitive) to perindopril or any of the
other ingredients of
Perindopril Tablets (see Further Information, section 6) or to any
other ACE inhibitor.

if you have had sym

Summary of Product characteristics

OBJECT 1
PERINDOPRIL 8 MG TABLETS
Summary of Product Characteristics Updated 15-Nov-2016 | Accord
Healthcare Limited
1. Name of the medicinal product
Perindopril 8 mg Tablets.
2. Qualitative and quantitative composition
Each tablet contains perindopril tert-butylamine 8 mg equivalent to
6.676 mg perindopril.
Excipient(s) with known effect: Lactose anhydrous. Each tablet
contains 170.40 mg lactose anhydrous.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Tablet.
White capsule shaped, biconvex tablets, engraved “P” Bisect
“8”on one side and plain on the other side.
The tablets can be divided into equal halves.
4. Clinical particulars
4.1 Therapeutic indications
Hypertension Treatment of hypertension
Heart Failure Treatment of symptomatic heart failure
Stable coronary artery disease Reduction of risk of cardiac events in
patients with a history of myocardial
infraction and/or revascularisation.
Perindopril can be used alone or in combination with other
antihypertensive agents (see sections 4.3, 4.4,
4.5 and 5.1).
4.2 Posology and method of administration
Posology
It is recommended that Perindopril is taken once daily in the morning
before a meal. The dose should be
individualised according to the patient profile (see section 4.4 and
blood pressure response.
Hypertension
Perindopril can be used alone or in combination with other
antihypertensive agents (see sections 4.3, 4.4,
4.5 and 5.1). The recommended starting dose is 4 mg given once daily
in the morning. Patients with a
strongly activated renin-angiotensin-aldosterone system (in
particular, renovascular hypertension, salt
and/or volume depletion, cardiac decompensation or severe
hypertension) may experience an excessive
drop in blood pressure following the initial dose. A starting dose of
2 mg is recommended in such patients
and the initiation of treatment should take place under medical
supervision. The dose may be increased to
8 mg once daily after one month of treatment. Symptomatic hypotension
may occur following initiation